3 Healthcare Stock Stories For Midweek Wellness

Forest Laboratories (NYSE:FRX): Closing price $37.04

On Wednesday, Forest and Almirall announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial that studies the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

frx

Regeneron Pharmaceuticals (NASDAQ:REGN): Closing price $236.33

Analyst Terence Flynn at Goldman Sachs reiterated a Buy the shares and upgraded the price target from $230 to $240. In his report, Flynn noted, “We recently conducted a survey of 41 US cardiologists/lipidologists to gauge awareness of the anti-PCSK9 drug class (REGN/Sanofi’s ‘727 and AMGN’s ‘145) as well as potential future prescribing patterns. The results of the survey were encouraging, as awareness was high and physicians project to use this class of drugs in 25 to 50 percent of their patients one year after approval. We see this ultimately as a $5billion to $10 billion class at peak assuming ongoing CV outcomes trials are positive in 2018. As a result we are raising our ‘727 peak sales to $3 billion to $5 billion from $3 billion.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

regn

Amgen (NASDAQ: AMGN): Closing price $104.52

Goldman Sachs has upgraded Amgen shares from Neutral to Conviction Buy with a price target of $130, up from $100. Analyst Terence Flynn is more positive on Amgen compared with Biogen IDEC (NASDAQ: BIIB), and sees a “more favorable combination of catalysts and upside potential.” Flynn noted that ”AMGN is entering a period where several of its key biologic franchises are coming off patent between 4Q13 and 2H15. However, we believe this is anticipated by investors and for the most part already reflected in consensus estimates. We project that AMGN’s pipeline and own biosimilars (first launch in 2017) will allow it to replace the potential revenue that could be lost to competition and grow its base.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

amgn

Don’t Miss: Chart of the Day: These 5 American Giants Lead the Way.